Serina Therapeutics, Inc. (SER)

Market Cap	46.64M
Revenue (ttm)	130,000
Net Income (ttm)	-12.71M
Shares Out	10.25M
EPS (ttm)	-1.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,555
Open	4.700
Previous Close	4.720
Day's Range	4.550 - 4.780
52-Week Range	3.810 - 10.280
Beta	n/a
Analysts	Strong Buy
Price Target	13.00 (+185.71%)
Earnings Date	Nov 11, 2025

About SER

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In additio...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2018
• Employees: 13
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: SER
• Website: https://serinatherapeutics.com

Analyst Summary

According to 2 analysts, the average rating for SER stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 185.71% from the latest price.

Price Target

$13.0

(185.71% upside)

Analyst Consensus: Strong Buy